Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and alpha-ketoamides

No Thumbnail Available
Issue Date
2016-01
Embargo End Date
Authors
Kim, Yunjeong
Kankanamalage, Anushka C. Galasiti
Damalanka, Vishnu C.
Weerawarna, Pathum M.
Groutas, William C.
Chang, Kyeong-Ok
Advisor
Citation

Yunjeong KimAnushka C. Galasiti KankanamalageVishnu C. DamalankaPathum M. WeerawarnaWilliam C. GroutasKyeong-Ok Chang. 2016. Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and α-ketoamides. Antiviral Research January 2016, Vol.125:84–91, doi:10.1016/j.antiviral.2015.11.010

Abstract

Enterovirus D68 (EV-D68) is an emerging pathogen responsible for mild to severe respiratory infections that occur mostly in infants, children and teenagers. EV-D68, one of more than 100 non-polio enteroviruses, is acid-labile and biologically similar to human rhinoviruses (HRV) (originally classified as HRV87). However, there is no approved preventive or therapeutic measure against EV-D68, HRV, or other enteroviruses. In this study, we evaluated the antiviral activity of series of dipeptidyl compounds against EV-D68 and HRV strains, and demonstrated that several peptidyl aldehyde and alpha-ketoamide peptidyl compounds are potent inhibitors of EV-D68 and HRV strains with high in-vitro therapeutic indices (>1000). One of the alpha-ketoamide compounds is shown to have favorable pharmacokinetics profiles, including a favorable oral bioavailability in rats. Recent successful development of alpha-ketoamide protease inhibitors against hepatitis C virus suggests these compounds may have a high potential for further optimization and development against emerging EV-D68, as well as HRV. (C) 2015 Elsevier B.V. All rights reserved.

Table of Content
Description
Click on the DOI link to access the article (may not be free).
publication.page.dc.relation.uri
DOI